Is there an optimal adjunct therapy to traditional cytotoxic induction?
The traditional cytotoxic induction regimen for acute myeloid leukemia (AML) is seven days of standard-dose cytarabine and three days of an anthracycline antibiotic (such as daunorubicin or idarubicin), commonly known as “7 + 3.” Many studies have been conducted to find an additional agent that migh...
Gespeichert in:
| Veröffentlicht in: | Best practice & research. Clinical haematology 2021-12, Vol.34 (4), p.101326-101326, Article 101326 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 101326 |
|---|---|
| container_issue | 4 |
| container_start_page | 101326 |
| container_title | Best practice & research. Clinical haematology |
| container_volume | 34 |
| creator | Michaelis, Laura C. |
| description | The traditional cytotoxic induction regimen for acute myeloid leukemia (AML) is seven days of standard-dose cytarabine and three days of an anthracycline antibiotic (such as daunorubicin or idarubicin), commonly known as “7 + 3.” Many studies have been conducted to find an additional agent that might improve efficacy. Data from select studies has shown, in certain populations, benefit to adding cladribine, clofarabine and lomustine to a traditional backbone. For mutation-based chemotherapy regimens, midostaurin with 7 + 3 is the current standard of care for FLT3-mutant, younger AML patients. As we learn more about the synergism of molecular agents and traditional anti-cancer treatments, we can hopefully develop novel regimens without abandoning some of the benefits of these mutation agnostic historical therapies. |
| doi_str_mv | 10.1016/j.beha.2021.101326 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2607308582</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1521692621000918</els_id><sourcerecordid>2607308582</sourcerecordid><originalsourceid>FETCH-LOGICAL-c307t-fa8a3be314de2aba3d7105621a4d25f485a7e7d6fb8f16f8251366f62b7753233</originalsourceid><addsrcrecordid>eNp9kE9LxDAQxYMo7rr6BTxIj1665k-btiCILLouLHjRc0iTKZvSbWqSivvtbe3q0dMM8948eD-ErgleEkz4Xb0sYSeXFFMyHhjlJ2hOUkZjUtDkdNwpiXlB-QxdeF9jzFhB2TmasSTnKS_yOVpvfBR24CCSbWS7YPayiaSu-1aFH0F2hyjYKDipTTC2HWR1CDbYL6Mi0-pejdeHS3RWycbD1XEu0Pvz09vqJd6-rjerx22sGM5CXMlcshIYSTRQWUqmM4JTTolMNE2rJE9lBpnmVZlXhFc5TQnjvOK0zLKhGGMLdDvlds5-9OCD2BuvoGlkC7b3gnKcMZynOR2sdLIqZ713UInODfXcQRAsRoCiFiNAMQIUE8Dh6eaY35d70H8vv8QGw_1kgKHlpwEnvDLQKtDGgQpCW_Nf_jdFLIDu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2607308582</pqid></control><display><type>article</type><title>Is there an optimal adjunct therapy to traditional cytotoxic induction?</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Michaelis, Laura C.</creator><creatorcontrib>Michaelis, Laura C.</creatorcontrib><description>The traditional cytotoxic induction regimen for acute myeloid leukemia (AML) is seven days of standard-dose cytarabine and three days of an anthracycline antibiotic (such as daunorubicin or idarubicin), commonly known as “7 + 3.” Many studies have been conducted to find an additional agent that might improve efficacy. Data from select studies has shown, in certain populations, benefit to adding cladribine, clofarabine and lomustine to a traditional backbone. For mutation-based chemotherapy regimens, midostaurin with 7 + 3 is the current standard of care for FLT3-mutant, younger AML patients. As we learn more about the synergism of molecular agents and traditional anti-cancer treatments, we can hopefully develop novel regimens without abandoning some of the benefits of these mutation agnostic historical therapies.</description><identifier>ISSN: 1521-6926</identifier><identifier>EISSN: 1532-1924</identifier><identifier>DOI: 10.1016/j.beha.2021.101326</identifier><identifier>PMID: 34865698</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Acute myeloid leukemia (AML) ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Cladribine ; Clofarabine ; Cytarabine ; Cytarabine - therapeutic use ; Daunorubicin ; Daunorubicin - therapeutic use ; Gemtuzumab ; Humans ; Idarubicin ; Idarubicin - therapeutic use ; Induction Chemotherapy ; Leukemia, Myeloid, Acute - drug therapy ; Leukemia, Myeloid, Acute - genetics ; Lomustine ; Midostaurin ; Remission Induction</subject><ispartof>Best practice & research. Clinical haematology, 2021-12, Vol.34 (4), p.101326-101326, Article 101326</ispartof><rights>2021 Elsevier Ltd</rights><rights>Copyright © 2021 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c307t-fa8a3be314de2aba3d7105621a4d25f485a7e7d6fb8f16f8251366f62b7753233</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1521692621000918$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34865698$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Michaelis, Laura C.</creatorcontrib><title>Is there an optimal adjunct therapy to traditional cytotoxic induction?</title><title>Best practice & research. Clinical haematology</title><addtitle>Best Pract Res Clin Haematol</addtitle><description>The traditional cytotoxic induction regimen for acute myeloid leukemia (AML) is seven days of standard-dose cytarabine and three days of an anthracycline antibiotic (such as daunorubicin or idarubicin), commonly known as “7 + 3.” Many studies have been conducted to find an additional agent that might improve efficacy. Data from select studies has shown, in certain populations, benefit to adding cladribine, clofarabine and lomustine to a traditional backbone. For mutation-based chemotherapy regimens, midostaurin with 7 + 3 is the current standard of care for FLT3-mutant, younger AML patients. As we learn more about the synergism of molecular agents and traditional anti-cancer treatments, we can hopefully develop novel regimens without abandoning some of the benefits of these mutation agnostic historical therapies.</description><subject>Acute myeloid leukemia (AML)</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Cladribine</subject><subject>Clofarabine</subject><subject>Cytarabine</subject><subject>Cytarabine - therapeutic use</subject><subject>Daunorubicin</subject><subject>Daunorubicin - therapeutic use</subject><subject>Gemtuzumab</subject><subject>Humans</subject><subject>Idarubicin</subject><subject>Idarubicin - therapeutic use</subject><subject>Induction Chemotherapy</subject><subject>Leukemia, Myeloid, Acute - drug therapy</subject><subject>Leukemia, Myeloid, Acute - genetics</subject><subject>Lomustine</subject><subject>Midostaurin</subject><subject>Remission Induction</subject><issn>1521-6926</issn><issn>1532-1924</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE9LxDAQxYMo7rr6BTxIj1665k-btiCILLouLHjRc0iTKZvSbWqSivvtbe3q0dMM8948eD-ErgleEkz4Xb0sYSeXFFMyHhjlJ2hOUkZjUtDkdNwpiXlB-QxdeF9jzFhB2TmasSTnKS_yOVpvfBR24CCSbWS7YPayiaSu-1aFH0F2hyjYKDipTTC2HWR1CDbYL6Mi0-pejdeHS3RWycbD1XEu0Pvz09vqJd6-rjerx22sGM5CXMlcshIYSTRQWUqmM4JTTolMNE2rJE9lBpnmVZlXhFc5TQnjvOK0zLKhGGMLdDvlds5-9OCD2BuvoGlkC7b3gnKcMZynOR2sdLIqZ713UInODfXcQRAsRoCiFiNAMQIUE8Dh6eaY35d70H8vv8QGw_1kgKHlpwEnvDLQKtDGgQpCW_Nf_jdFLIDu</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Michaelis, Laura C.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202112</creationdate><title>Is there an optimal adjunct therapy to traditional cytotoxic induction?</title><author>Michaelis, Laura C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c307t-fa8a3be314de2aba3d7105621a4d25f485a7e7d6fb8f16f8251366f62b7753233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Acute myeloid leukemia (AML)</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Cladribine</topic><topic>Clofarabine</topic><topic>Cytarabine</topic><topic>Cytarabine - therapeutic use</topic><topic>Daunorubicin</topic><topic>Daunorubicin - therapeutic use</topic><topic>Gemtuzumab</topic><topic>Humans</topic><topic>Idarubicin</topic><topic>Idarubicin - therapeutic use</topic><topic>Induction Chemotherapy</topic><topic>Leukemia, Myeloid, Acute - drug therapy</topic><topic>Leukemia, Myeloid, Acute - genetics</topic><topic>Lomustine</topic><topic>Midostaurin</topic><topic>Remission Induction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Michaelis, Laura C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Best practice & research. Clinical haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Michaelis, Laura C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Is there an optimal adjunct therapy to traditional cytotoxic induction?</atitle><jtitle>Best practice & research. Clinical haematology</jtitle><addtitle>Best Pract Res Clin Haematol</addtitle><date>2021-12</date><risdate>2021</risdate><volume>34</volume><issue>4</issue><spage>101326</spage><epage>101326</epage><pages>101326-101326</pages><artnum>101326</artnum><issn>1521-6926</issn><eissn>1532-1924</eissn><abstract>The traditional cytotoxic induction regimen for acute myeloid leukemia (AML) is seven days of standard-dose cytarabine and three days of an anthracycline antibiotic (such as daunorubicin or idarubicin), commonly known as “7 + 3.” Many studies have been conducted to find an additional agent that might improve efficacy. Data from select studies has shown, in certain populations, benefit to adding cladribine, clofarabine and lomustine to a traditional backbone. For mutation-based chemotherapy regimens, midostaurin with 7 + 3 is the current standard of care for FLT3-mutant, younger AML patients. As we learn more about the synergism of molecular agents and traditional anti-cancer treatments, we can hopefully develop novel regimens without abandoning some of the benefits of these mutation agnostic historical therapies.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>34865698</pmid><doi>10.1016/j.beha.2021.101326</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1521-6926 |
| ispartof | Best practice & research. Clinical haematology, 2021-12, Vol.34 (4), p.101326-101326, Article 101326 |
| issn | 1521-6926 1532-1924 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2607308582 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Acute myeloid leukemia (AML) Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cladribine Clofarabine Cytarabine Cytarabine - therapeutic use Daunorubicin Daunorubicin - therapeutic use Gemtuzumab Humans Idarubicin Idarubicin - therapeutic use Induction Chemotherapy Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - genetics Lomustine Midostaurin Remission Induction |
| title | Is there an optimal adjunct therapy to traditional cytotoxic induction? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T22%3A44%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Is%20there%20an%20optimal%20adjunct%20therapy%20to%20traditional%20cytotoxic%20induction?&rft.jtitle=Best%20practice%20&%20research.%20Clinical%20haematology&rft.au=Michaelis,%20Laura%20C.&rft.date=2021-12&rft.volume=34&rft.issue=4&rft.spage=101326&rft.epage=101326&rft.pages=101326-101326&rft.artnum=101326&rft.issn=1521-6926&rft.eissn=1532-1924&rft_id=info:doi/10.1016/j.beha.2021.101326&rft_dat=%3Cproquest_cross%3E2607308582%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2607308582&rft_id=info:pmid/34865698&rft_els_id=S1521692621000918&rfr_iscdi=true |